Brian Walker, Ph. D. LITTLE ROCK – Brian Walker, Ph.D., has joined the University of Arkansas for Medical Sciences (UAMS) as a professor of medicine in the College of Medicine and director of the Myeloma Institute’s basic research team. Walker’s most recent post was as a senior research scientist with the Centre for [...]
With FDA approved new Immunotherapy Drugs for Myeloma, are Auto and Allo Transplants on the Way Out?
In just the past 2 months, 3 new drugs for myeloma treatment have been approved by the FDA. With so many more options for immunotherapy drugs coming up, will transplants continue to be an integral part of myeloma treatment? Tune in December 15th at 10 am ET to listen to myeloma advocates and survivors discuss [...]
The Myeloma Institute Social Work Department will host a Patient Support Seminar entitled “Handling the Holidays – a gift of healthy tips” on Thursday, December 3 from 5:30 – 7:00 PM. The seminar will be held in the Betsy Blass Boardroom on the 10th floor of the Cancer Institute and refreshments will be provided.
Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma. Read more here: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472875.htm
Guess the Diagnosis: Case 1 Watch the video segments Case-Based Peer Perspectives on Targeted Oncology Lisa B. is a 47-year-old female store owner from St. Louis, with a 10-month history of fatigue, night sweats, and weight loss. She presents to her PCP with generalized lymphadenopathy, most prominent in the cervical region; there is no polyneuropathy, [...]
"Gareth Morgan is a true world leader in the field of myeloma research." Read more about Myeloma Institute Director, Dr. Gareth Morgan, in yesterday's high profile section in the Arkansas Democrat-Gazette newspaper. http://www.arkansasonline.com/news/2015/sep/27/gareth-john-morgan-intent-on-cancer-cur/
Dr. Faith Davies is a professor of medicine and the director of the Phase I Clinical Trials program for both the Myeloma Institute and the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences. She is recognized internationally for her focus on innovative targeted molecular therapies and her expertise in the [...]
Originally from the UK but now at UAMS, Dr. Gareth Morgan, MD, PhD believes it to be a very valuable test and uses the information that the test provides to alter treatment approaches. He notes: We did significant work comparing the GEP70 to i-FISH, the interface FISH which people out there use as a standard [...]
Testing for genetic risk factors may improve myeloma treatments by identifying those at risk for more aggressive disease. This study, published in the Journal of Clinicial Oncology and led by researchers in London, including our own Myeloma Institute Director, Dr. Gareth Morgan, is the first to link genetic mutations in myeloma cells to the chances [...]